|
Document Type |
: |
Thesis |
|
Document Title |
: |
ENHANCEMENT OF THE THERAPEUTIC EFFICIENCY OF ANTICANCER DRUGS USING MESOPOROUS SILICA NANOPARTICLES تحسين الكفاءة العلاجية للعقار المضاد للأورام بإستخدرام جزيئات الميزوبورس سيليكا النانومترية كحامل للعقار |
|
Subject |
: |
Faculty of Sciences |
|
Document Language |
: |
Arabic |
|
Abstract |
: |
This study aims to prepare mesoporousilica nanoparticles (MSNPs) coated with polyethylene glycol (PEG) as a nanodelivery system for curcumin (Cur) forming PEG-MSNPs-Cur. This formulation will improve Cur bioavailability to be an effective chemopreventive and therapeutic agent. The physicochemical properties of PEG-MSNPs-Cur were investigated using different techniques. This novel nanocarrier showed high Cur loading efficiency as well as exhibiting a pH and time dependent drug sustained release profile.
The antitumor activities of PEG-MSNPs-Cur were studied both in vitro and in vivo and compared with free-Cur. In vitro studies were conducted on two different human cancer cell lines: liver cancer cells (HepG2) and cervical cancer cells (HeLa). Compared with free-Cur, PEG-MSNPs-Cur showed higher cellular uptake in a cell type and time dependent manner. Furthermore, PEG-MSNPs-Cur displayed significant cytotoxicity against HepG2 and HeLa cells in a dose and time dependent way. PEG-MSNPs-Cur-treated HepG2 cells exhibited marked cell cycle arrest at G2/M compared to free-Cur-treated cells.
For in vivo studies, we designed two cancer treatment protocols: Tumor Chemoprevention Protocol (TCP) and Tumor Reduction Protocol (TRP).
TCP is based on the strategy of minimizing or preventing cancer. Two separate mice groups were received chemopreventive doses of free-Cur, and PEG-MSNPs-Cur, respectively, (4 doses, on alternating days, 2.88 mg/kg) before tumor inoculation. On the 7th day, the experimental groups were inoculated with Ehrlich ascites tumor (EAT) and TCP continued where the two mice groups received 6 additional therapeutic doses over a period of 14 days.
TRP is a conventional treatment based on the strategy of treating tumor-bearing mice. Separate groups of mice were EAT inoculated, and were allowed to grow for 7 days. Then, the treatment was started where the mice groups were received PBS, free-Cur, and PEG-MSNPs-Cur, respectively, (6 doses, on alternating days, 2.88 mg/kg).
The integrated in vivo results demonstrated that TCP exhibited high therapeutic efficacy compared with other protocol. |
|
Supervisor |
: |
Dr. Nihal Elbialy |
|
Thesis Type |
: |
Master Thesis |
|
Publishing Year |
: |
1439 AH
2018 AD |
|
Added Date |
: |
Sunday, May 27, 2018 |
|
Researchers
| بلسم فهد صوفي | Sofi, Balsam Fahad | Researcher | Master | |
|